Multiple Myeloma: International Myeloma Foundation

We are international

Webcasts from the 2012 Annual Meeting of the American Society of Clinical Oncology

share |

email this page

Velcade

Others

ASCO 2012: Dr. Nooka - Survival outcomes of early autologous stem cell transplant (ASCT) followed by lenalidomide, bortezomib, and dexamethasone (RVD) maintenance in patients with high-risk multiple myeloma (MM)

Ajay Nooka, MD
Winship Cancer Center
Emory University
Atlanta, Georgia, USA

ASCO 2012: Dr. Orlowski - Phase II, randomized, double blind, placebo-controlled study comparing siltuximab plus bortezomib versus bortezomib alone in pts with relapsed/refractory multiple myeloma

Robert Orlowski, MD
MD Anderson Cancer Center
Houston, Texas, USA